CXCR4 expression in early breast cancer and risk of distant recurrence

Oncologist

Volumn 14, Issue 12, 2009, Pages 1182-1188

  Andre, Fabrice ^a,b   Xia, Weiya ^b   Conforti, Rosa ^a   Wei, Yongkun ^b   Boulet, Thomas ^a   Tomasic, Gorana ^a   Spielmann, Marc ^a   Zoubir, Moustafa ^a   Berrada, Narjiss ^a   Arriagada, Rodrigo ^a   Hortobagyi, Gabriel N ^b   Hung, Mien Chie ^b   Pusztai, Lajos ^b   Delaloge, Suzette ^a   Michiels, Stefan ^a   Cristofanilli, Massimo ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Bone metastases; Breast cancer; CXCR4 expression; Recurrence

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; STROMAL CELL DERIVED FACTOR 1; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISTANT METASTASIS; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CXCR4; SURVIVAL RATE;

EID: 75449099136     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0161     Document Type: Article

References (30)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:99-101.
2. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-128.
3. Powles T, McCroskey E, Paterson A. Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 2006;12:s6301-s6304.
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350: 1655-1664.
5. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004; 14:181-185.
6. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
7. Andre F, Cabioglu N, Assi H et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006;17:945-951.
8. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-549.
9. Li YM, Pan Y, Wei Y et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004;6:459-469.
10. Kaifi JT, Yekebas EF, Schurr P et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005;97:1840-1847.
11. Cabioglu N, Sahin A, DoucetMet al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 2005;22:39-46.
12. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-348.
13. Arriagada R, Spielmann M, Koscielny S et al. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 2005;44:458-466.
14. Contesso G, Mouriesse H, Friedman S et al. The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987;5: 1378-1386.
15. Conforti R, Boulet T, Tomasic G et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: A biomarker study from two randomized trials. Ann Oncol 2007;18:1477-1483.
16. Arriagada R, Rutqvist LE, Kramar A et al. Competing risks determining event-free survival in early breast cancer. Br J Cancer 1992;66:951-957.
17. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/ CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006;25:573-587.
18. Taichman RS, Cooper C, Keller ET et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
19. Geminder H, Sagi-Assif O, Goldberg L et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167:4747- 4757.
20. Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:5615-5621.
21. Schabath H, Runz S, Joumaa S et al. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006;119:314-325.
22. Smid M, Wang Y, Klijn JG et al. Genes associated with breast cancer metastatic to the bone. J Clin Oncol 2006;24:2261-2267.
23. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-3224.
24. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201.
25. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360: 679-691.
26. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008;2:197-203.
27. Jones DH, Nakashima T, Sanchez OH et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692- 696.
28. Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564-1571.
29. Liang Z, Wu T, Lou H et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004;64:4302-4308.
30. Takenaga M, Tamamura H, Hiramatsu K et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004;320: 226-232.